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Although there are some newly developed options to treat dystonia, its medical treat-
ment is not always satisfactory. Zolpidem, an imidazopyridine agonist with a high afﬁnity
on benzodiazepine subtype receptor BZ1 (ω1), was found to improve clinical symptoms
of dystonia in a limited number of case reports. To investigate what subtype of dystonia
is responsive to the therapy, we conducted an open label study to assess the efﬁcacy
of zolpidem (5–20mg) in 34 patients suffering from miscellaneous types of dystonia using
the Burke–Fahn–MarsdenDystonia Rating Scale (BFMDRS). Patientswere entered into the
study if they had been refractory to other medications as evaluated by BFMDRS (no change
in the previous two successive visits). After zolpidem therapy, the scores in the patients
as a whole were decreased from 7.2± 7.9 to 5.5± 5.0 (P = 0.042). Patients with general-
ized dystonia,Meige syndrome/blepharospasm, and hand dystonia improved in the scale by
27.8, 17.8, and 31.0%, respectively, whereas no improvementwas found in cervical dystonia
patients. Overall response rate among patients were comparable to that of trihexyphenidyl.
Zolpidem may be a therapeutic option for generalized dystonia, Meige syndrome, and hand
dystonia including musician’s. Drowsiness was the dose-limiting factor.
Keywords: generalized dystonia, Meige syndrome, hand dystonia, zolpidem
INTRODUCTION
Dystonia is a syndrome of sustained muscle contractions causing
twisting and repetitive movements or abnormal postures (Fahn
et al., 1998). Although there are several options to treat dystonia,
its medical treatment is notoriously difﬁcult and often unsuccess-
ful. Zolpidem, an imidazopyridine agonist with a high afﬁnity to
benzodiazepine subtype receptor BZ1 (ω1; Holm and Goa, 2000),
is reported to improve basal ganglia disease including Parkinson’s
disease (Daniele et al., 1997) and various types of dystonia (Evi-
dente, 2002; Garretto et al., 2004; An et al., 2008; Park et al., 2009)
Despite these case reports, zolpidem has not been tested in a large
number of patients with various subtypes of dystonia. Here we
report two dystonia patients who improved remarkably by oral
zolpidem therapy, and assessed treatment outcome of zolpidem
in 34 medically intractable patients suffering from miscellaneous
types of dystonia, in order to determine what subtypes of dystonia
are good candidates for zolpidem trial.
MATERIALS AND METHODS
PATIENTS
Dystonia patients were selected, not in randomized, nor con-
trolled design, from those seen at Tokushima University Hos-
pital and Takeda General Hospital, Japan. The diagnosis of pri-
mary dystonia was made according to standard criteria (Albanese
et al., 2006): Major exclusion criteria were the presence of
brain lesion in basal ganglia detected by 1.5 T magnetic reso-
nance image and the past history of antipsychotics administra-
tion. We enrolled 34 patients with dystonia, who were treated
with trihexyphenidyl (4–12mg/day), clonazepam (0.5–3mg/day),
baclofen (15–60mg/day), and others (9 generalized dystonia; 10
Meige syndrome/blepharospasm; 7 cervical dystonia; 8 hand dys-
tonia). All patients were refractory to further dose increases of oral
medications other than zolpidem. Their doses were unchanged if
continued in the zolpidem trial. Of all, 23 patients were resistant
to botulinum toxin typeA (OnabotulinumtoxinA: 50–200 IU, 0.5–
8ml) injections. The refractoriness was evidenced by the lack of
improvement in the Burke–Fahn–Marsden Dystonia Rating Scale
(BFMDRS) in the last two visits. All focal dystonia patients (Meige
syndrome/blepharospasm, cervical dystonia, and hand dystonia)
did not spread to multiple body parts during 1 year follow up.
One patient underwent palidal stimulation before entry. Their
clinical characteristics are summarized in Table 1. Their mean age
was 48.8± 15.8 years; mean disease duration was 5.2 ± 5.1 years.
Zolpidem was started at 10mg/day (once a day in the evening),
later increased or decreased in dosage (5–20mg/day: once or twice
a day in the morning and evening) depending on the tolerability
and the beneﬁt. The mean dosage of zolpidem was 11.2± 5.12mg.
ASSESSMENTS
All patients were assessed before and 1month after zolpidem
administrationusingBFMDRS, including theDystoniaMovement
Scale (Part I) and Disability Scale (Part II; Burke et al., 1985).
We deﬁned the global improvement as follows; more than 40%
improvement in BFMDRS as“remarkable improvement,” less than
40% improvement as “mild improvement,” and no change in the
scale as “ no improvement.”
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Table 1 | Patients’ summary.
Generalized dystonia
(n=9)
Meige/blepharospasm
(n=10)
Cervical dystonia
(n=7)
Hand dystonia
(n=8)
Total
(n=34)
Gender (male/female) 3M/6F 6M/4F 7M/0F 5M/3F 21M/13F
Age 38.3±19.4 60.6±9.6 45.7±14.4 48.4±10.1 48.8±15.8
Duration (years) 4.6±6.8 3.6±3.2 6.0±4.9 7.4±5.2 5.2±5.1
BFMDRS: before 15.8±10.0 6.2±5.4 2.4±1.1 2.9±2.0 7.2±7.9
BFMDRS: after 11.4±5.7 5.1±3.0 2.4±1.1 2.0±0.9 *5.5±5.0
Zolpidem (mg/day) 12.2±6.2 12.0±4.8 10±0 8.8±5.1 10.9±4.8
BTX 6 10 6 1 26
*P=0.041 vs before administration (t-test).
Standard protocol approvals, registrations, and patient consents
This study was approved by JSPS Grants-in-Aid for Scientiﬁc
Research (No. 21390269), and informed consent was obtained
from all patients.
Data analysis
Statistical analyses were made using t -test, results were considered
signiﬁcant at a level of P < 0.05.
RESULTS
CASE REPORTS
Case 1
A 36-years-old man, who was a clarinet player, had 1-year his-
tory of cramps during the performance. His physical condition
and mental condition was normal, and there were no neurologic
abnormalities. At the age 35, he noticed an abnormal cramp on
the left little ﬁnger during clarinet performance. The symptoms
gradually worsened over time, ﬁnally he became no longer able to
play the clarinet in the concert. He had been on medications with
trihexyphenidyl up to 12mg/day and clonazepam (1–3mg/day)
with no beneﬁts.
At the age of 36-years-old, we tried zolpidem on him, which
improved his symptoms dramatically to the extent that he had
no problems in the performance. He took 10mg of zolpidem
before playing the clarinet, and found the beneﬁcial effect within
30min, its durations of action being about 3 h. One year later, he
was still using zolpidem 10mg once or twice a day for occasional
concert.
Case 2
A-20-years-old woman, who was a softball player, had 1-year his-
tory for lower limbs dystonia. Her physical condition and mental
conditionwas normal, and therewere noneurologic abnormalities
except for dystonic symptoms on the bilateral lower limbs. At the
age 19, she noticed an abnormal inversion of the left ankle during
walking. The symptoms gradually worsened, and she developed
difﬁculty inwalking because of her lower limbsmuscle hyperactiv-
ity. Her dystonic symptoms did not change with or without shoes.
She was tried medication with trihexyphenidyl (up to 12mg/day),
baclofen (up to 30mg/day), and gabapentin, with no effect. At age
20, she became unable to walk, or to bend her knees and ankles.
She was referred to us with a diagnosis of lower limb dystonia
(Figure 1).
We treated her with zolpidem oral monotherapy with a dose
up to 20mg/day. Three days after the therapy, she found it easy to
bend her right knee and could stand without any help. She could
walk on day 7, and ﬁnally she could climb up and down stairs on
day 14. One year later, she was still on zolpidem, with continued
beneﬁt.
Effects of zolpidem in miscellaneous types of dystonia
Table 1 depicts summary of the patients. BFMDRS in total dysto-
nia patientswere signiﬁcantly decreased from7.2± 7.9 to 5.5± 5.0
(P = 0.041).
As for subtypes of dystonia, the scale decreased on the aver-
age in generalized, Meige syndrome/blepharospasm, and hand
dystonia (Table 1). After zolpidem, 3 of 9 generalized dystonia
(33%), 2 of 10 Meige syndrome/blepharospasm (20%), and 3 of
8 hand dystonia patients (38%) improved in the motor subscale
of BFMDRS (generalized dystonia; 29–75% improvement, Meige
syndrome/blepharospasm; 33–39% improvement, hand dystonia;
33–67% improvement),whereas cervical dystonia patients didnot.
Overall, the present study showed that 8 of 34 dystonia patients
(24%) responded to zolpidem.
Adverse effects associated with zolpidem were drowsiness,
amnesia, and abnormal behavior (somnambulism). Moderate or
severe drowsiness occurred in eight patients (three cases of respon-
ders and ﬁve non-responders), and transient amnesia occurred in
four patients (two responders and two non-responders).
DISCUSSION
Here we described the outcome of zolpidem trial in patients with
miscellaneous types of dystonia,whose symptomshadbeen refrac-
tory to other medications. In all dystonia patients, 24% of the
patients responded to zolpidem, and remarkable improvements
were found particularly in generalized and hand dystonias. No
improvement was found in cervical dystonia. Despite the differ-
ent outcome measures and clinical protocols, the present data
are comparable to the efﬁcacy of trihexyphenidyl in a previous
study reporting improvements in 44% for generalized dystonia
patients, 63% for Meige syndrome/blepharospasm, and 28% for
focal dystonia patients (Jabbari et al., 1989).
Our result has a limitation that the design was not a ran-
domized controlled trial. Indeed this is a pivotal study so that
the conclusion regarding efﬁcacy of zolpidem should be cau-
tious and other studies are needed to replicate our results, It is
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FIGURE 1 | (A) It is before treatment. She could not walk without help
because of left dominant lower limbs dystonic spasm. (B)We started
zolpidem 20mg/day monotherapy, and at the day 14, she could walk without
any support, despite the persisting inversion of the left ankle.
however unlikely that the beneﬁcial effects are entirely placebo-
based, because the patients had been equally tried on other med-
ications with no beneﬁt before enrollment. Moreover, improve-
ment in the scale of the whole patients was signiﬁcant. We
therefore consider that zolpidem is a useful option for treating
dystonia.
It was reported that some of adult onset primary focal dystonia
patients spread proximally or contralaterally or become general-
ized within several years of symptom onset (Weiss et al., 2006).
For that reason, we assessed all patients using BFMDRS, one of
the major clinical dystonia scales for generalized dystonia, in this
study. It would be desirable to evaluate on the scale suitable for
each types of dystonia in future trials,with divided subtypes, being
randomized, blinded, and placebo-controlled.
For the patients with generalized dystonia, Meige syn-
drome/blepharospasm, and hand dystonia, mild to remark-
able improvements (29–75% improvement in BFMDRS) were
observed, whereas no signiﬁcant changes were found for cervi-
cal dystonia after zolpidem (Figure 2). Despite the small number
of cases, blepharospasm was also refractory. Even within the same
subtype, responsiveness to zolpidem considerably varied among
patients.
We used zolpidem 5–20mg/day for the patients with dystonia,
and drowsiness was tolerated for most of the subjects. Eight out
of 34 subjects complained relatively persistent drowsiness (3 cases
of responders and 5 of non-responders). No correlation between
drowsiness and effects to dystonia syndrome was found. It is how-
ever possible that doses used in this study may not be large enough
to obtain the maximal beneﬁt, because the previous studies used
the doses up to 50–70mg/day (Garretto et al., 2004; Young et al.,
2008).
Focal hand dystonia (writer’s cramp and other occupational
cramps) is a primary dystonia produced by the excessive co-
contraction of antagonistic muscles of the hand and forearm
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FIGURE 2 | Before and 1month after zolpidem administration,
patients with patients with generalized dystonia, Meige syndrome/
blepharospasm, cervical dystonia, and hand dystonia experienced
improvement in the motor subscale of Burke–Fahn–Marsden
Dystonia Rating Scale (BFMDRS). *Case 1; **Case 2; [9][10],
blepharospasm.
(Sheehy and Marsden, 1982). In our study, 38% of the hand dys-
tonia patients improved after zolpidem. In past study, botulinum
toxin treatment of hand dystonia showed less favorable beneﬁts
than cervical dystonia or blepharospasm (Karp et al., 1994). Musi-
cians’ cramp or dystonia of other highly skilled performance are
even more difﬁcult to obtain the satisfactory outcome. Zolpidem
is worth being tried on such patients as Case 1 in our study.
Zolpidem is an imidazopyridine agonist with a high afﬁnity on
the benzodiazepine site of GABAA receptors containingα1 subunit
in combination with β2 and γ2 subunits (McKernan and Whiting,
1996; Sanna et al., 2002), equivalent to ω1 subtypes, present in
interneurons in all brain areas including the hippocampus, the
cortex, and the cerebellar Purkinje cells (McKernan and Whiting,
1996). Recently a high density of zolpidem binding sites was found
in the thalamus (Licata et al., 2009) and the subthalamic nucleus
(Chen et al., 2007), and possibly the globus pallidus (Duncan et al.,
1995; Chen et al., 2004). After binding to these sites, zolpidem
could enhance inhibitory pathways in the basal gangliamotor loop,
accounting for the clinical improvement in dystonia.
Lack of responsiveness in cervical dystonia is unexplained in
the present study. Intriguingly, the clinical improvement in cervi-
cal dystonia after globus pallidus internus deep brain stimulation
(GPi-DBS) was reported to be less satisfactory than other sub-
types (Starr et al., 2006; Lee et al., 2007). It might be possible that
GPi-DBS and zolpidem could have similar mechanisms of action.
In conclusion, zolpidemmaybe auseful option for treating gen-
eralized/hand dystonias, andMeige syndromewho do not respond
to botulinum toxin or oral medications.
ACKNOWLEDGMENTS
This study was supported by JSPS Grants-in-Aid for Scientiﬁc
Research (No. 21390269). We thank the patients and their families
for participating in this study.
SUPPLEMENTARY MATERIAL
The Movies S1–S5 for this article can be found online at http://
www.frontiersin.org/Movement_Disorders/10.3389/fneur.2012.
00058/abstract
REFERENCES
Albanese, A., Barnes, M. P., Bhatia, K.
P., Fernandez-Alvarez, E., Filippini,
G., Gasser, T., Krauss, J. K., New-
ton, A., Rektor, I., Savoiardo, M.,
and Valls-Solè, J. (2006). A system-
atic review on the diagnosis and
treatment of primary (idiopathic)
dystonia and dystonia plus syn-
dromes: report of an EFNS/MDS-
ES task force. Eur. J. Neurol. 13,
433–444.
An, J. Y., Kim, J. S., Kim, Y. I., and Lee,
K. S. (2008). Successful treatment
of the Meige syndrome with oral
zolpidem monotherapy. Mov. Dis-
ord. 23, 1619–1621.
Burke, R. E., Fahn, S., Marsden, C. D.,
Bressman, S. B., Moskowitz, C., and
Friedman, J. (1985). Validity and
reliability of a rating scale for the pri-
mary torsion dystonias. Neurology
35, 73–77.
Chen, L., Savio, C. C., and Yung, W.
H. (2004). Electrophysiological and
behavioral effects of zolpidem in rat
globus pallidus. Exp. Neurol. 186,
212–220.
Chen, L., Xie, J. X., Fung, K. S., and
Yung,W. H. (2007). Zolpidem mod-
ulatesGABA(A) receptor function in
subthalamic nucleus. Neurosci. Res.
58, 77–85.
Daniele, A., Albanese, A., Gainotti,
G., Gregori, B., and Bartolomeo, P.
(1997). Zolpidem in Parkinson’s dis-
ease. Lancet 349, 1222–1223.
Duncan, G. E., Breese, G. R., Criswell,
H. E., McCown, T. J., Herbert, J.
S., Devaud, L. L., and Morrow,
A. L. (1995). Distribution of [3H]
zolpidem binding sites in relation to
messenger RNA encoding the α1, β2
and γ2 subunits of GABAA recep-
tors in rat brain. Neuroscience 64,
1113–1128.
Evidente, V. G. (2002). Zolpidem
improves dystonia in Lubag or X-
linked dystonia-parkinsonism syn-
drome. Neurology 26, 662–663.
Fahn, S., Bressman, S. B., and Mars-
den, C. D. (1998). Classiﬁcation of
dystonia. Adv. Neurol. 78, 1–10.
Garretto, N. S., Bueri, J. A., Rey, R. D.,
Arakaki, T., Nano, G. V., and Man-
cuso, M. (2004). Improvement of
Frontiers in Neurology | Movement Disorders April 2012 | Volume 3 | Article 58 | 4
Miyazaki et al. Zolpidem therapy in dystonia
blepharospasm with zolpidem. Mov.
Disord. 19, 967–968.
Holm, K. J., and Goa, K. L. (2000).
Zolpidem: an update of its
pharmacology, therapeutic efﬁcacy
and tolerability in the treatment of
insomnia. Drugs 59, 865–889.
Jabbari, B., Scherokaman, B., Gunder-
son, C. H., Rosenberg, M. L.,
and Miller, J. (1989). Treatment of
movement disorders with trihexy-
phenidyle. Mov. Disord. 4, 202–212.
Karp, B. I., Cole, R. A., Cohen, L. G.,
Grill, S., Lou, J. S., and Hallett, M.
(1994). Long-term botulinum toxin
treatment of focal hand dystonia.
Neurology 44, 70–76.
Lee, J. Y., Deogankar, M., and Rezai,
A. (2007). Deep brain stimula-
tion of globus pallidus internus for
dystonia.ParkinsonismRelat.Disord.
13, 261–265.
Licata, S. C., Jensen, J. E., Pene-
tar, D. M., Prescot, A. P., Lukas,
S. E., and Renshaw, P. F. (2009).
A therapeutic dose of zolpidem
reduces thalamic GABA in healthy
volunteers: a proton MRS study at
4 T. Psychopharmacology (Berl.) 203,
819–829.
McKernan, R. M., and Whiting, P.
J. (1996). Which GABAA-receptor
subtypes really occur in the brain?
Tends Neurosci. 19, 139–143.
Park, I. S., Kim, J. S., An, J. Y., Kim,
Y. L., and Lee, K. S. (2009). Excel-
lent response to oral zolpidem in
a sporadic case of the myoclonus
dystonia syndrome. Mov. Disord. 24,
2172–2173.
Sanna,E.,Busonero, F.,Talani,G.,Carta,
M.,Massa, F., Peis,M.,Maciocco,M.,
and Biggio, G. (2002). Comparison
of the effects of zaleplon, zolpidem,
and triazolam at various GABA(A)
receptor subtypes. Eur. J. Pharmacol.
451, 103–110.
Sheehy, M. P., and Marsden, C. D.
(1982). Writer’s cramp: a focal dys-
tonia. Brain 105, 461–480.
Starr, P. A., Turner, R. S., Rau, G.,
Lindsey, N., Heath, S., Volz, M.,
Ostrem, J. L., and Marks, W. J.
Jr. (2006). Microelectrode-guided
implantation of deep stimulators
into the globus pallidus internus for
dystonia: techniques, electrode loca-
tions, and out comes. J. Neurosurg.
104, 488–501.
Weiss, E. M., Hershey, T., Karimi, M.,
Racette, B., Tabbal, S. D., Mink, J.
W., Paniello, R. C., and Perlmutter,
J. S. (2006). Relative risk of spread
of symptoms among the focal onset
primary dystonias. Mov. Disord. 21,
1175–1181.
Young, J., Kim, J. S., Kim, Y. I., and Lee,
K. S. (2008). Successful treatment of
the Meige syndrome with oral zolpi-
dem monotherapy. Mov. Disord. 23,
1619–1620.
Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any
commercial or ﬁnancial relationships
that could be construed as a potential
conﬂict of interest.
Received: 06 October 2011; accepted: 28
March 2012; published online: 17 April
2012.
Citation: Miyazaki Y, Sako W, Asanuma
K, Izumi Y, Miki T and Kaji R (2012)
Efﬁcacy of zolpidem for dystonia: a study
among different subtypes. Front. Neur.
3:58. doi: 10.3389/fneur.2012.00058
This article was submitted to Frontiers
in Movement Disorders, a specialty of
Frontiers in Neurology.
Copyright © 2012 Miyazaki, Sako,
Asanuma, Izumi, Miki and Kaji. This is
an open-access article distributed under
the terms of the Creative Commons Attri-
bution Non Commercial License, which
permits non-commercial use, distribu-
tion, and reproduction in other forums,
provided the original authors and source
are credited.
www.frontiersin.org April 2012 | Volume 3 | Article 58 | 5
